Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

ALNA
Allena Pharmaceuticals, Inc. Common Stock
stock NASDAQ

Inactive
Sep 7, 2022
0.0750USD+3.164%(+0.0023)276,971,676
Pre-market
0.00USD-100.000%(-0.07)0
After-hours
0.00USD0.000%(0.00)0
OverviewHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 5, 2022
11:07AM EST  Stocks That Hit 52-Week Lows On Wednesday   Benzinga
Jan 4, 2022
08:11AM EST  The Daily Biotech Pulse: Liquidia Jumps On New CEO Appointment, Spectrum, Aravive Secure New Funding, Allena To Explore Strategic Alternatives   Benzinga
05:00AM EST  -- ALLN-346, an orally administered enzyme in development for the treatment of hyperuricemia and gout, demonstrates a statistically significant reduction in serum uric acid and a well-tolerated safety profile in first cohort of patients with hyperuricemia and chronic kidney disease in the Phase 2a Study 201   GlobeNewswire Inc
Nov 15, 2021
04:05PM EST  Allena Pharmaceuticals to Participate in the Stifel 2021 Virtual   GlobeNewswire Inc
Nov 10, 2021
05:38PM EST  Allena Pharmaceuticals Q3 EPS $(0.17) Up From $(0.22) YoY   Benzinga
Nov 3, 2021
09:17AM EDT  Allena Pharmaceuticals Says Receives Fast Track Designation From FDA For Development Of ALLN-346 For Chronic Treatment Of Hyperuricemia In Patients With Gout And Advanced Chronic Kidney Disease   Benzinga
08:00AM EDT  - Novel oral therapeutic candidate ALLN-346 targets uric acid in the intestinal tract -   GlobeNewswire Inc
Sep 29, 2021
08:03AM EDT  Allena Pharmaceuticals Commences Dosing Of Gout Patients In Second Phase 2a Trial Of ALLN-346   Benzinga
08:00AM EDT  - Fourteen-day study focused on high unmet need in patients with gout and chronic kidney disease -   GlobeNewswire Inc
Sep 9, 2021
08:30AM EDT  Allena Pharmaceuticals to Participate in H.C.   GlobeNewswire Inc
Aug 10, 2021
04:51PM EDT  Allena Pharmaceuticals Q2 EPS $(0.24) Up From $(0.26) YoY   Benzinga
Aug 3, 2021
04:05PM EDT  Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ   GlobeNewswire Inc
09:54AM EDT  Allena Pharmaceuticals Granted U.S. Patent Titled 'Compositions, methods, and devices for dialysis'   Benzinga
Jul 28, 2021
07:33AM EDT  The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal   Benzinga
Jul 20, 2021
08:20AM EDT  The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street   Benzinga
Jul 16, 2021
07:37AM EDT  The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study   Benzinga
Jul 15, 2021
08:08AM EDT  The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs   Benzinga
Jul 14, 2021
07:48AM EDT  The Daily Biotech Pulse: ScPharma's Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues   Benzinga
07:08AM EDT  Allena Pharma Stock Under Pressure After Equity Raise Of $28M   Benzinga
Jul 13, 2021
11:44PM EDT  Allena Pharmaceuticals Announces $28 Million Registered Direct   GlobeNewswire Inc
Jul 12, 2021
11:07AM EDT  Allena Revises Interim Reloxaliase Analysis Targeted Now For Q1 2022; ALLN-346 Phase 2 Data On Track For End Of 2021   Benzinga
08:10AM EDT  Allena Pharmaceuticals Provides Update on Clinical Development Programs; Co. Reports 'ALLN-346 successfully completes Phase 1b safety study; on track to start two Phase 2a studies in Q3 2021 with initial data expected in Q4 2021'   Benzinga
08:00AM EDT  -ALLN-346 successfully completes Phase 1b safety study; on track to start two Phase 2a studies in Q3 2021 with initial data expected in Q4 2021-   GlobeNewswire Inc
Jul 8, 2021
04:18PM EDT  Allena Pharmaceuticals, Inc. to Present at the Ladenburg Thalmann   GlobeNewswire Inc
Jul 7, 2021
04:15PM EDT  Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ   GlobeNewswire Inc
Jun 8, 2021
08:30AM EDT  Allena Pharmaceuticals to Host Key Opinion Leader Webinar Focused   GlobeNewswire Inc
May 11, 2021
10:30AM EDT  Allena Pharmaceuticals shares were trading lower after the company reported Q1 earnings results.   Benzinga
08:16AM EDT  Allena Pharmaceuticals Q1 EPS $(0.21) Up From $(0.31) YoY   Benzinga
08:00AM EDT  Allena Pharmaceuticals Reports First Quarter 2021 Financial   GlobeNewswire Inc
May 4, 2021
04:01PM EDT  Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ   GlobeNewswire Inc
Apr 21, 2021
07:31AM EDT  The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue   Benzinga
Apr 8, 2021
08:00AM EDT  Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ   GlobeNewswire Inc
Apr 7, 2021
08:11AM EDT  Allena Appoints Mark Fitzpatrick To Its Board   RTTNews
08:00AM EDT  Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced the appointment of Mark J. Fitzpatrick to its board of directors.   GlobeNewswire Inc
Mar 30, 2021
06:11AM EDT  Allena Pharmaceuticals Files Prospectus Supplement Related To Issuance, Sale Of Up To $50M Of Common Stock   Benzinga
Mar 9, 2021
09:16AM EST  Allena Pharmaceuticals Q4 EPS $(0.24) Up From $(0.47) YoY   Benzinga
07:00AM EST  -- Reloxaliase continues to progress through ongoing pivotal Phase 3 URIROX-2 trial for enteric hyperoxaluria --   GlobeNewswire Inc
Feb 24, 2021
08:00AM EST  Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that company management will participate in two upcoming investor conferences in March:   GlobeNewswire Inc
Feb 2, 2021
08:02AM EST  Allena Pharmaceuticals Appoints Richard D. Katz, M.D. as Chief Financial Officer   Benzinga
08:01AM EST  Allena Pharmaceuticals Appoints Richard D. Katz, M.D. as Chief   GlobeNewswire Inc
Jan 4, 2021
08:00AM EST  Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that company management will participate in two upcoming investor conferences in January:   GlobeNewswire Inc
Dec 10, 2020
05:14PM EST  Steve Cohen's Point72 Asset Management Reports In 13G Filing An 8% Stake In Allena Pharmaceuticals   Benzinga
05:13PM EST  Point72 Asset Management Reports In 13G Filing An 8% Stake In Allena Pharmaceuticals   Benzinga
Dec 2, 2020
07:35AM EST  The Daily Biotech Pulse: Pfizer-BioNTech Vaccine Gets Temporary UK Authorization, Ovid's Trial Disappointment, Vanda Snags FDA Nod   Benzinga
Dec 1, 2020
09:47PM EST  Allena Pharmaceuticals Increases Previously Announced Bought Deal   GlobeNewswire Inc
05:00PM EST  Allena Pharma Reports 8M Share Bought-Deal Offering At $1.25/Share   Benzinga
05:00PM EST  Allena Pharmaceuticals Announces $10.0 Million Bought Deal Offering   GlobeNewswire Inc
08:00AM EST  Allena Pharmaceuticals Announces Appointment of David J. Clark,   GlobeNewswire Inc
Nov 30, 2020
08:08AM EST  Allena Pharmaceuticals Announces Initial Data From Phase 1 Trial Of ALLN-346   Benzinga
08:08AM EST  Allena Pharmaceuticals Announces Single-Ascending Doses of ALLN-346 Oral Enzyme Well-Tolerated; Advancing to Phase 1b Multiple-Ascending Dose Study and Phase 2 Proof-of-Concept Trial With Initial Data from Both Studies Expected in Second Half of 2021   Benzinga
08:00AM EST  -- Single-Ascending Doses ofALLN-346 Oral Enzyme Well-Tolerated --- Non-Absorption of ALLN-346 Demonstrated --- Advancing to Phase 1b Multiple-Ascending Dose Study and Phase 2 Proof-of-Concept Trial; Initial Data from Both Studies Expected in Second Half of 2021 --   GlobeNewswire Inc
Nov 24, 2020
08:00AM EST  Allena Pharmaceuticals to Present Virtually at Evercore ISI 3rd   GlobeNewswire Inc
Nov 9, 2020
08:18AM EST  Allena Pharmaceuticals Q3 EPS $(0.22) Up From $(0.57) YoY   Benzinga
08:00AM EST  -- Presented Data at 53rd Annual Meeting of the American Society of Nephrology (ASN) Highlighting Consistent Treatment Effects Across Phase 2 and 3 Clinical Trials of Reloxaliase in Enteric Hyperoxaluria (EH) --   GlobeNewswire Inc
Nov 3, 2020
08:01AM EST  Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that company management will participate in three upcoming investor conferences in November:   GlobeNewswire Inc
Oct 5, 2020
08:14AM EDT  Allena Pharmaceuticals Appoints Ann Miller To Its Board   RTTNews
08:00AM EDT  Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced the appointment of Ann Miller, M.D., to its board of directors.   GlobeNewswire Inc
Sep 30, 2020
10:53AM EDT  Why Allena Pharmaceuticals Is Trading Higher Today   Benzinga
08:03AM EDT  Allena Pharmaceuticals Announces $25M Strategic Convertible Debt Financing Agreement With Pontifax Ventures   Benzinga
08:00AM EDT  -- Extends Allenas Cash Runway into 4Q 2021 --- Debt Can be Converted into Equity at a Price of $4.10 Per Share --   GlobeNewswire Inc
Sep 8, 2020
08:09AM EDT  Allena Pharmaceuticals Doses First Subject In Phase 1 Clinical Trial Of ALLN-346 In Development For Treatment Of Hyperuricemia In Patients With Gout, Advanced Chronic Kidney Disease   Benzinga
08:00AM EDT  Allena Pharmaceuticals Doses First Subject in Phase 1 Clinical   GlobeNewswire Inc
Sep 3, 2020
08:00AM EDT  Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that company management will participate in fireside chats at two investor conferences in September:   GlobeNewswire Inc
Aug 5, 2020
08:44AM EDT  Allena Pharmaceuticals Q2 EPS $(0.26) Up From $(0.54) YoY   Benzinga
08:00AM EDT  -- Expanding URIROX-2 Trial Sites; Interim Analysis on Track for the First Quarter of 2022 -   GlobeNewswire Inc
Aug 4, 2020
08:00AM EDT  Allena Pharmaceuticals to Present at 2020 Wedbush PacGrow   GlobeNewswire Inc
Jul 27, 2020
04:55PM EDT  Allena Pharmaceuticals Announces $5M Bought Deal Offering   Benzinga
04:54PM EDT  Allena Pharmaceuticals Announces $5.0 Million Bought Deal Offering   GlobeNewswire Inc
Jul 22, 2020
07:00AM EDT  U.S. Small Cap Stocks Could Outperform The Market During The   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC